BMS Renews RAN Agreement with 2.0
February 25, 2021
The Recombinant Antibody Network (RAN), a consortium comprising research groups from UC San Francisco, the University of Chicago, and the University of Toronto, has entered into a second research collaboration with Celgene that aims to create and develop high-performance recombinant antibodies against diverse targets in human cells.
The first RAN collaboration was launched in 2015 with Celgene, which was later acquired by Bristol Myers Squibb in 2019.